Pyrazinamide resistance in Mycobacterium tuberculosis fails to bite?

Pathogens and Disease

Volumn 73, Issue 6, 2015, Pages

  den Hertog, Alice L ^a   Sengstake, Sarah ^a   Anthony, Richard M ^a  

^a ROYAL TROPICAL INSTITUTE   (Netherlands)

Author keywords

Fitness; Multidrug resistance; Mycobacterium tuberculosis; Pyrazinamide; Resistance; Transmission

Indexed keywords

PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; EPIDEMIOLOGY; HUMAN; MEDICAL LITERATURE; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; VIRUS TRANSMISSION; DISEASE TRANSMISSION; DRUG EFFECTS; MICROBIOLOGY; PHYSIOLOGY; TRANSMISSION; TUBERCULOSIS; VIRULENCE;

ANTITUBERCULAR AGENTS; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSIS; VIRULENCE;

EID: 84973427694     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1093/femspd/ftv037     Document Type: Article

References (39)

1. Aung KJM, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen'formultidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung D 2014;18:1180-87.
2. Barnett M, Busby SR, Mitchison DA. Tubercle bacilli resistant to isoniazid: virulence and response to treatment with isoniazid in guinea-pigs andmice. Brit J Exp Pathol 1953;34:568-81.
3. Bergval IL, Schuitema ARJ, Klatser PR, et al. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemoth 2009;64:515-23.
4. Betts JC, Lukey PT, Robb LC, et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002;43: 717-31.
5. Boshoff HIM, Xu X, Tahlan K, Dowd CS, et al. Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem 2008;283:19329-41.
6. Brown TJ, Tansel O, French GL. Simultaneous identification and typing of multi-drug-resistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB. J Med Microbiol 2000;49:651-6.
7. Budzik JM, Jarlsberg LG, Higashi J, et al. Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California. PLoS ONE 2014;9: e95645.
8. Casali N, Nikolayevskyy V, Balabanova Y, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 2014;46:279-86.
9. Chang KC, Yew WW, Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Ch 2011;55: 4499-505.
10. Daum LT, Fourie PB, Bhattacharyya S, et al. Next-generation sequencing for identifying pyrazinamide resistance in Mycobacterium tuberculosis. Clin Infect Dis 2014;58:903-4.
11. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970;20:810-4.
12. Doyle AC. The Memoirs of Sherlock Holmes, Silver Blaze. Great Britain: George Newnes, 1892,1:1-31
13. Franke MF, Becerra MC, Tierney DB, et al. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc 2015;12:674-9.
14. Günther G, van Leth F, Alexandru S, et al. Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis 2015;21: 409-16.
15. Hoffner S, Angeby K, Sturegard E, et al. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience. Int J Tuberc Lung Dis 2013;17:1486-90.
16. Kim S, Kurokawa D, Watanabe K, et al. Brucella abortus nicotinamidase (PncA) contributes to its intracellular replication and infectivity in mice. FEMS Microbiol Lett 2004;234:289-95.
17. Koeck J-L, Fabre M, Simon F, et al. Clinical characteristics of the smooth tubercle bacilli 'Mycobacterium canettii' infection suggest the existence of an environmental reservoir. Clin Microbiol Infect 2011;17:1013-9.
18. LoBue PA, Betacourt W, Peter C, et al. Epidemiology of Mycobacterium bovis disease in San Diego County, 1994-2000. Int J Tuberc Lung Dis 2003;7:180-5.
19. Louw GE, Warren RM, Donald PR, et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006;10:802-7.
20. Miotto P, Cabibbe AM, Feuerriegel S, et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: amulticenter study. MBio 2014;5:e01819-4.
21. Morgan M, Kalantri S, Flores L, et al. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and metaanalysis. BMC Infect Dis 2005;28:62.
22. Naidoo P, du Toit E, Dunbar R, et al. A comparison of multidrugresistant tuberculosis treatment commencement times in MDRTBPlus line probe assay and Xpert R δ MTB/RIF-based algorithms in a routine operational setting in Cape Town. PLoS ONE. 2014;9:e103328.
23. Purser JE, Lawrenz MB, Caimano MJ, et al. A plasmid-encoded nicotinamidase (PncA) is essential for infectivity of Borrelia burgdorferi in a mammalian host. Mol Microbiol 2003;48: 753-64.
24. Rouse DA, DeVito JA, Li Z, et al. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalaseperoxidase activities and isoniazid resistance. Mol Microbiol 1996;22:583-92.
25. Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Ch 1997;41:540-3.
26. Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011;333:1630-2.
27. Singh P, Mishra AK, Malonia SK, et al. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria. J Commun Dis 2006;38:288-98.
28. Stoffels K, Mathys V, Fauville-Dufaux M, et al. Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Ch 2012;56:5186-93.
29. Thomas TA, Heysell SK, Houpt ER, et al. Outbreak of pyrazinamide-monoresistant tuberculosis identified using genotype cluster and social media analysis. Int J Tuberc Lung Dis 2014;18:552-8.
30. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010;14:131-40.
31. Van Deun A, Salim MAH, Das APK, et al. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004;8:560-7.
32. van Soolingen D, de Haas PE, van Doorn HR, et al. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 2000;182:1788-90.
33. Vilchèze C, Weinrick B, Wong K-W, et al. NAD+ auxotrophy is bacteriocidal for the tubercle bacilli. Mol Microbiol 2010;76:365-77.
34. Wang F, Shao L, Fan X, et al. Evolution and transmission patterns of extensively drug-resistant tuberculosis in china. Antimicrob Agents Ch 2015;59:818-25.
35. WHO. Guidelines for the Programmatic Management of Drugresistant Tuberculosis. 2011, http://whqlibdoc.who.int/publications/2011/9789241501583?eng.pdf?ua=1 (27 February 2015, date last accessed).
36. WHO. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. 2014 http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809 ?eng.pdf?ua=1&ua=1 (27 February 2015, date last accessed)).
37. Yang J, Liu Y, Bi J, et al. Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide. Mol Microbiol 2015;95:791-803.
38. Yeager RL, Munroe WGC, Dessau FI. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952;65:523-46.
39. Zhang S, Chen J, Shi W, et al. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect 2013;2:e34.